Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biological markers in urologic cancer.

P H Lange, H N Winfield

    Cancer
    |August 1, 1987
    PubMed
    Summary

    Tumor markers are crucial for managing urologic cancers like testicular and prostate cancer. New advancements, including monoclonal antibodies, promise expanded use in diagnosing and treating various urological malignancies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Experimental models and methods in antibody targeting of renal cell carcinoma.

    Methods in molecular medicine·2011
    Same author

    Robotic assisted laparoscopic pyeloplasty.

    Minerva urologica e nefrologica = The Italian journal of urology and nephrology·2007
    Same author

    A novel monoclonal antibody 107-1A4 with high prostate specificity: generation, characterization of antigen expression, and targeting of human prostate cancer xenografts.

    Prostate cancer and prostatic diseases·2002
    Same author

    A transperitoneal laparoscopic approach to endourology.

    Current urology reports·2002
    Same author

    Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2001
    Same author

    The percentage of free prostate-specific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy.

    BJU international·2001

    Area of Science:

    • Uro-oncology
    • Biomarker Discovery
    • Cancer Diagnostics

    Background:

    • Tumor markers (TMs) are vital in managing urologic cancers.
    • Specific markers are established for testicular and prostate cancers.
    • Current limitations exist for markers in renal cell carcinoma.

    Purpose of the Study:

    • To review the current role of tumor markers in urologic cancer management.
    • To highlight emerging biomarkers and technologies.
    • To discuss future directions in uro-oncology diagnostics.

    Main Methods:

    • Review of established and novel tumor markers in urologic oncology.
    • Discussion of diagnostic techniques including serological assays, DNA analysis, and immunohistochemistry.
    • Exploration of the potential of monoclonal antibodies.

    Main Results:

    • Established markers like alpha-fetoprotein and human chorionic gonadotropin are key in testicular cancer management.
    • Prostatic specific antigen is increasingly important for prostate cancer monitoring.
    • DNA analysis and tissue markers show promise for bladder cancer detection.

    Conclusions:

    • Tumor markers are indispensable tools in urologic cancer care.
    • Emerging technologies, particularly monoclonal antibodies, are expected to significantly advance diagnostic and therapeutic capabilities.
    • Clinical judgment remains essential for effective marker utilization.

    Related Experiment Videos